SELLAS Life Sciences Group, Inc.

Contributing Author

Recent Articles by SELLAS Life Sciences Group, Inc.

May-14	SELLAS Life Sciences to Participate in Upcoming Investor Conferences SLS +13.63% GlobeNewswire
May-12	SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update SLS +25.10% SLS GlobeNewswire
Mar-19	SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update SLS -8.46% SLS +5.05% GlobeNewswire
Mar-17	SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference SLS -5.97% GlobeNewswire
Mar-12	SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 SLS -8.21% GlobeNewswire
Jan-14	SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe SLS GlobeNewswire
Dec-29	SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) SLS +16.72% GlobeNewswire
Dec-07	SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 SLS GlobeNewswire
Nov-12	SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update SLS GlobeNewswire
Nov-03	SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting SLS GlobeNewswire
Oct-27	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds SLS GlobeNewswire
Oct-22	SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum SLS GlobeNewswire
Oct-13	SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 SLS GlobeNewswire
Sep-30	SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update SLS GlobeNewswire
Sep-11	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds SLS GlobeNewswire
Aug-12	SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update SLS GlobeNewswire
Aug-07	SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification SLS GlobeNewswire
Jul-15	SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study SLS GlobeNewswire
Jul-07	SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board SLS GlobeNewswire
Jun-24	SELLAS Life Sciences to be Added to Russell 3000 and Russell 2000 Indexes SLS GlobeNewswire
Jun-05	SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts SLS GlobeNewswire
Jun-02	SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting SLS -7.60% GlobeNewswire
May-20	SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase SLS +10.86% GlobeNewswire
May-15	SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML SLS +5.96% GlobeNewswire
May-13	SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update SLS -8.44% SLS +7.09% GlobeNewswire

SELLAS Life Sciences Group, Inc.

Recent Articles by SELLAS Life Sciences Group, Inc.

Upgrade your Finviz experience